Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK to close three research units, open four more amid hopes for sales growth in 2012

This article was originally published in Scrip

Executive Summary

GlaxoSmithKline's CEO Sir Andrew Witty is predicting a return to sales growth this year as the UK firm's radical shake-up of discovery and early development starts to pay off. The firm saw sales on a reported basis decline by 4% to £27.4 billion last year, driven down by the dramatic reduction in pandemic flu product sales in 2011 versus 2010, the loss of sales of the antidiabetic Avandia (rosiglitazone), which was withdrawn or vastly restricted in most markets in 2010 for cardiovascular safety reasons, and other factors including declines for the now off-patent antiviral Valtrex (valaciclovir), foreign exchange and austerity measures by governments. European price cuts alone took £320 million off 2011 sales, GSK said.

Topics

Related Companies

UsernamePublicRestriction

Register

SC016171

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel